 |
ASCO GuidelinesAuthor: American Society of Clinical Oncology (ASCO)
ASCO Guidelines Podcast breaks down pivotal recommendations from the latest evidence-based clinical practice guidance and provides insight into daily patient care. Listen to stay up to date with the ever-evolving landscape of cancer research and treatment. Language: en-us Genres: Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it Trailer: |
Listen Now...
Treatment of Multiple Myeloma: ASCO Living Guideline Update 2026.1.1
Monday, 29 June, 2026
Dr. Rahul Banerjee joins the podcast to discuss the latest update to the living guideline on the treatment of multiple myeloma. He explains how sensational results from the MajesTEC-3 trial, which evaluated teclistamab plus daratumumab, prompted a major shift in the recommendations for patients with relapsed or refractory disease. Dr. Banerjee details why immunotherapies, specifically CAR T-cell therapy and bispecific antibodies, are now the preferred treatment options at first relapse over traditional triplets. He also provides context on evidence that did not lead to recommendation changes, the importance of individualized decision-making when choosing between immunotherapy options, and what future updates may be on the horizon, including data on CELMoDs. Read the full living guideline, "Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1," at www.ascopubs.org/guidelines/treatment-multiple-myeloma-asco-living-guideline
